Do analysts recommend KPRX or APLM?

Kiora Pharmaceuticals currently has a consensus target price of $10.00, suggesting a potential upside of 280.23%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, KPRX or APLM?

Kiora Pharmaceuticals has higher revenue and earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kiora Pharmaceuticals $16.02M 0.73 -$10.84M -$2.71 N/A Apollomics $8.50M 5.06 -$10.94M N/A N/A

Is KPRX or APLM more profitable?

Apollomics' return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Kiora Pharmaceuticals N/A -59.30% -41.23% Apollomics N/A N/A N/A

Which has higher earnings and valuation, KPRX or ATHE?

Alterity Therapeutics has lower revenue, but higher earnings than Kiora Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kiora Pharmaceuticals $16.02M 0.73 -$10.84M -$2.71 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is KPRX or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Kiora Pharmaceuticals N/A -59.30% -41.23% Alterity Therapeutics N/A N/A N/A

Do analysts prefer KPRX or GNTA?

Kiora Pharmaceuticals currently has a consensus target price of $10.00, suggesting a potential upside of 280.23%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, KPRX or GNTA?

Genenta Science has lower revenue, but higher earnings than Kiora Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kiora Pharmaceuticals $16.02M 0.73 -$10.84M -$2.71 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Is KPRX or GNTA more profitable?

Genenta Science's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Kiora Pharmaceuticals N/A -59.30% -41.23% Genenta Science N/A N/A N/A

Kiora Pharmaceuticals (KPRX) Competitors

$2.63 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$2.68 +0.05 (+1.94%)

As of 07/2/2026 07:55 PM Eastern

Compare

KPRX vs. NBRV, APLM, ELUT, ATHE, and GNTA

Should you buy Kiora Pharmaceuticals stock or one of its competitors? MarketBeat compares Kiora Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kiora Pharmaceuticals include Nabriva Therapeutics (NBRV), Apollomics (APLM), Elutia (ELUT), Alterity Therapeutics (ATHE), and Genenta Science (GNTA). These companies are all part of the "pharmaceutical products" industry.

How does Kiora Pharmaceuticals compare to Nabriva Therapeutics?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

In the previous week, Kiora Pharmaceuticals' average media sentiment score of 0.00 equaled Nabriva Therapeutics'average media sentiment score.

Company	Overall Sentiment
Kiora Pharmaceuticals	Neutral
Nabriva Therapeutics	Neutral

Kiora Pharmaceuticals has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Kiora Pharmaceuticals' return on equity of -59.30% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

Kiora Pharmaceuticals currently has a consensus price target of $10.00, indicating a potential upside of 280.23%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Kiora Pharmaceuticals is more favorable than Nabriva Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kiora Pharmaceuticals has higher earnings, but lower revenue than Nabriva Therapeutics. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.71	N/A
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A

Kiora Pharmaceuticals has a beta of -0.4, meaning that its stock price is 140% less volatile than the broader market. Comparatively, Nabriva Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market.

Summary

Kiora Pharmaceuticals beats Nabriva Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Apollomics?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Kiora Pharmaceuticals has a beta of -0.4, meaning that its share price is 140% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market.

In the previous week, Apollomics had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 1 mentions for Apollomics and 0 mentions for Kiora Pharmaceuticals. Apollomics' average media sentiment score of 0.59 beat Kiora Pharmaceuticals' score of 0.00 indicating that Apollomics is being referred to more favorably in the news media.

Company	Overall Sentiment
Kiora Pharmaceuticals	Neutral
Apollomics	Positive

Kiora Pharmaceuticals currently has a consensus target price of $10.00, suggesting a potential upside of 280.23%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Kiora Pharmaceuticals has higher revenue and earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.71	N/A
Apollomics	$8.50M	5.06	-$10.94M	N/A	N/A

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Apollomics' return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%
Apollomics	N/A	N/A	N/A

Summary

Kiora Pharmaceuticals beats Apollomics on 7 of the 13 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Elutia?

Elutia (NASDAQ:ELUT) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Elutia has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.4, suggesting that its share price is 140% less volatile than the broader market.

Elutia has a net margin of 312.09% compared to Kiora Pharmaceuticals' net margin of 0.00%. Elutia's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	312.09%	N/A	-53.97%
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

Elutia has higher earnings, but lower revenue than Kiora Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.46M	3.20	$53.38M	$0.86	1.08
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.71	N/A

Elutia currently has a consensus price target of $6.00, indicating a potential upside of 543.78%. Kiora Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 280.23%. Given Elutia's higher possible upside, analysts plainly believe Elutia is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

74.0% of Elutia shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 27.6% of Elutia shares are owned by company insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Elutia's average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Elutia	Neutral
Kiora Pharmaceuticals	Neutral

Summary

Elutia beats Kiora Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Alterity Therapeutics?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

Alterity Therapeutics' return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%
Alterity Therapeutics	N/A	N/A	N/A

Kiora Pharmaceuticals has a beta of -0.4, suggesting that its share price is 140% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

Kiora Pharmaceuticals presently has a consensus target price of $10.00, suggesting a potential upside of 280.23%. Alterity Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 142.54%. Given Kiora Pharmaceuticals' higher possible upside, equities research analysts plainly believe Kiora Pharmaceuticals is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Alterity Therapeutics has lower revenue, but higher earnings than Kiora Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.71	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

In the previous week, Alterity Therapeutics had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 1 mentions for Alterity Therapeutics and 0 mentions for Kiora Pharmaceuticals. Alterity Therapeutics' average media sentiment score of 1.00 beat Kiora Pharmaceuticals' score of 0.00 indicating that Alterity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Kiora Pharmaceuticals	Neutral
Alterity Therapeutics	Positive

Summary

Alterity Therapeutics beats Kiora Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Genenta Science?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Genenta Science has lower revenue, but higher earnings than Kiora Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.71	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

In the previous week, Kiora Pharmaceuticals' average media sentiment score of 0.00 equaled Genenta Science'saverage media sentiment score.

Company	Overall Sentiment
Kiora Pharmaceuticals	Neutral
Genenta Science	Neutral

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by company insiders. Comparatively, 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Genenta Science's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%
Genenta Science	N/A	N/A	N/A

Kiora Pharmaceuticals currently has a consensus target price of $10.00, suggesting a potential upside of 280.23%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Kiora Pharmaceuticals has a beta of -0.4, suggesting that its stock price is 140% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

Summary

Kiora Pharmaceuticals and Genenta Science tied by winning 5 of the 10 factors compared between the two stocks.

Get Kiora Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KPRX vs. The Competition

Export

Metric	Kiora Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.66M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	-0.97	20.06	28.02	24.70
Price / Sales	0.73	360.33	540.37	99.49
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	0.60	4.32	10.96	6.46
Net Income	-$10.84M	$64.45M	$3.57B	$337.01M
7 Day Performance	3.54%	2.97%	2.12%	1.69%
1 Month Performance	5.20%	6.83%	5.25%	3.81%
1 Year Performance	-8.17%	29.07%	33.29%	23.90%

Kiora Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KPRX Kiora Pharmaceuticals	1.9394 of 5 stars	$2.63 flat	$10.00 +280.2%	-8.2%	$11.66M	$16.02M	N/A	10	News Coverage
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	$45.46M	$35.59M	N/A	70	Gap Up
APLM Apollomics	0.7489 of 5 stars	$20.50 +2.0%	N/A	+200.7%	$44.12M	$8.50M	N/A	45
ELUT Elutia	3.1961 of 5 stars	$0.98 -4.7%	$6.00 +511.6%	-55.7%	$44.07M	$12.29M	N/A	180	Short Interest Decrease Gap Up
ATHE Alterity Therapeutics	3.2987 of 5 stars	$5.07 +2.2%	$10.00 +97.2%	+32.8%	$43.98M	N/A	N/A	10	Positive News Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KPRX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kiora Pharmaceuticals (KPRX) Competitors

KPRX vs. NBRV, APLM, ELUT, ATHE, and GNTA

How does Kiora Pharmaceuticals compare to Nabriva Therapeutics?

Summary

How does Kiora Pharmaceuticals compare to Apollomics?

Summary

How does Kiora Pharmaceuticals compare to Elutia?

Summary

How does Kiora Pharmaceuticals compare to Alterity Therapeutics?

Summary

How does Kiora Pharmaceuticals compare to Genenta Science?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPRX vs. The Competition

Kiora Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kiora Pharmaceuticals (KPRX) Competitors

KPRX vs. NBRV, APLM, ELUT, ATHE, and GNTA

How does Kiora Pharmaceuticals compare to Nabriva Therapeutics?

Does the media favor KPRX or NBRV?

Is KPRX or NBRV more profitable?

Do analysts prefer KPRX or NBRV?

Do insiders & institutionals hold more shares of KPRX or NBRV?

Which has stronger earnings and valuation, KPRX or NBRV?

Which has more risk & volatility, KPRX or NBRV?

Summary

How does Kiora Pharmaceuticals compare to Apollomics?

Which has more volatility and risk, KPRX or APLM?

Does the media prefer KPRX or APLM?

Do analysts recommend KPRX or APLM?

Which has better earnings and valuation, KPRX or APLM?

Do institutionals and insiders hold more shares of KPRX or APLM?

Is KPRX or APLM more profitable?

Summary

How does Kiora Pharmaceuticals compare to Elutia?

Which has more volatility and risk, ELUT or KPRX?

Is ELUT or KPRX more profitable?

Which has preferable earnings & valuation, ELUT or KPRX?

Do analysts rate ELUT or KPRX?

Do insiders & institutionals have more ownership in ELUT or KPRX?

Does the media refer more to ELUT or KPRX?

Summary

How does Kiora Pharmaceuticals compare to Alterity Therapeutics?

Is KPRX or ATHE more profitable?

Which has more volatility and risk, KPRX or ATHE?

Do analysts recommend KPRX or ATHE?

Do insiders and institutionals believe in KPRX or ATHE?

Which has higher earnings and valuation, KPRX or ATHE?

Does the media prefer KPRX or ATHE?

Summary

How does Kiora Pharmaceuticals compare to Genenta Science?

Which has stronger valuation & earnings, KPRX or GNTA?

Does the media prefer KPRX or GNTA?

Do insiders & institutionals hold more shares of KPRX or GNTA?

Is KPRX or GNTA more profitable?

Do analysts prefer KPRX or GNTA?

Which has more volatility & risk, KPRX or GNTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPRX vs. The Competition

Kiora Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools